Search
for
Sort by
Research 271–300 of 1000+
- 190 Deficiency of the Human Cysteine Protease Inhibitor Cystatin M/E Causes Hypotrichosis and Dry Skin
- Decision letter: A multi-scale model for hair follicles reveals heterogeneous domains driving rapid spatiotemporal hair growth patterning
- Exposure to gamma-rays at the telogen phase of the hair cycle inhibits hair follicle regeneration at the anagen phase in mice
- Activation of EGF and FGF signaling in developing mouse skin inhibits hair follicle morphogenesis
- Gfp-Expressing Vascularization of Gelfoam® as a Rapid in Vivo Assay of Angiogenesis Stimulators and Inhibitors
- ISID1108 - Comparison of ruxolitinib and a collagen-targeted PTH-based hair cycle stimulant on hair follicle counts and hair growth in the C3H/HeJ engrafted mouse model of alopecia areata.
- 1108 Comparison of ruxolitinib and a collagen-targeted PTH-based hair cycle stimulant on hair follicle counts and hair growth in the C3H/HeJ engrafted mouse model of alopecia areata
- High-throughput screening of small molecule Wnt/β-catenin activators for hair and nail growth
- Data from Targeting Superficial or Nodular Basal Cell Carcinoma with Topically Formulated Small Molecule Inhibitor of Smoothened
- Skin-specific expression of a truncated E1a oncoprotein binding to p105-Rb leads to abnormal hair follicle maturation without increased epidermal proliferation.
- 삼황사심탕의 항산화능 및 C57BL/6 마우스 모델에서의 발모 촉진효과
- Wound Healing: A Cellular Perspective
- Trends in the Development of New Drugs for Treatment of Benign Prostatic Hyperplasia
- Effect of Decellularized Extracellular Matrix Bioscaffolds Derived from Fibroblasts on Skin Wound Healing and Remodeling
- PERSPECTIVAS ACTUALES EN EL TRATAMIENTO DE LA ALOPECIA AREATA
- PERAN KELENJAR SEBASEA PADA ALOPESIA ANDROGENIK
- Studies of the modulation of MHC antigen and cell adhesion molecule expression on human dermal papilla cells
- Adverse Hair Reactions to New Targeted Therapies for Cancer
- The Frontal Fibrosing Alopecia Treatment Dilemma
- Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer
- Drugs and Hair Loss
- Molecular targeted therapies for cancer: Sorafenib mono�therapy and its combination with other therapies (Review)
- Advances in the Management of Cutaneous Toxicities of Targeted Therapies
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Chemotherapy-induced iatrogenic injury of skin: New drugs and new concepts
- Skin toxicity caused by EGFR antagonists—An autoinflammatory condition triggered by deregulated IL‐1 signaling?
- Dermatologic Reactions to Targeted Therapy
- Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital
- Cutaneous Drug Eruptions Associated with the Use of Biologies and Cutaneous Drug Eruptions Mimicking Specific Skin Diseases
- Management of Toxicities of Targeted Therapies